RELMADA THERAPEUTICS, INC. — Director's Dealing 2020

Mar 16, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2020-03-09

Reporting Person: Wessel Thomas (EVP, Head of R&D)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to purchase common stock	$45.61	2030-03-09	Common Stock (350000)		Direct

Footnotes

F1: Options granted on March 9, 2020 to purchase an aggregate of 350,000 shares of common stock. A total of 25% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal quarterly increments of 6.25% of the initial option grant over the following three year period.